204 related articles for article (PubMed ID: 24145547)
1. The fluoroquinolone levofloxacin triggers the transcriptional activation of iron transport genes that contribute to cell death in Streptococcus pneumoniae.
Ferrándiz MJ; de la Campa AG
Antimicrob Agents Chemother; 2014; 58(1):247-57. PubMed ID: 24145547
[TBL] [Abstract][Full Text] [Related]
2. Reactive Oxygen Species Contribute to the Bactericidal Effects of the Fluoroquinolone Moxifloxacin in Streptococcus pneumoniae.
Ferrándiz MJ; Martín-Galiano AJ; Arnanz C; Zimmerman T; de la Campa AG
Antimicrob Agents Chemother; 2016 Jan; 60(1):409-17. PubMed ID: 26525786
[TBL] [Abstract][Full Text] [Related]
3. Reactive Oxygen Species Production Is a Major Factor Directing the Postantibiotic Effect of Fluoroquinolones in Streptococcus pneumoniae.
García MT; Valenzuela MV; Ferrándiz MJ; de la Campa AG
Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31160286
[TBL] [Abstract][Full Text] [Related]
4. Antibacterial activity of a DNA topoisomerase I inhibitor versus fluoroquinolones in Streptococcus pneumoniae.
Valenzuela MV; Domenech M; Mateos-Martínez P; González-Camacho F; de la Campa AG; García MT
PLoS One; 2020; 15(11):e0241780. PubMed ID: 33141832
[TBL] [Abstract][Full Text] [Related]
5. In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae.
Louie A; Brown DL; Liu W; Kulawy RW; Deziel MR; Drusano GL
Antimicrob Agents Chemother; 2007 Nov; 51(11):3988-4000. PubMed ID: 17846144
[TBL] [Abstract][Full Text] [Related]
6. Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone-resistant Streptococcus pneumoniae: data from the global PROTEKT surveillance programme.
Canton R; Morosini M; Enright MC; Morrissey I
J Antimicrob Chemother; 2003 Dec; 52(6):944-52. PubMed ID: 14585861
[TBL] [Abstract][Full Text] [Related]
7. [Fluoroquinolone resistance determining region mutation in Streptococcus pneumonia isolates].
Zhang FF; Zhao CJ; Wang H
Zhonghua Jie He He Hu Xi Za Zhi; 2013 Dec; 36(12):940-4. PubMed ID: 24503427
[TBL] [Abstract][Full Text] [Related]
8. Cleavable-complex formation by wild-type and quinolone-resistant Streptococcus pneumoniae type II topoisomerases mediated by gemifloxacin and other fluoroquinolones.
Yague G; Morris JE; Pan XS; Gould KA; Fisher LM
Antimicrob Agents Chemother; 2002 Feb; 46(2):413-9. PubMed ID: 11796351
[TBL] [Abstract][Full Text] [Related]
9. The Transcriptome of
de la Campa AG; Ferrándiz MJ; Martín-Galiano AJ; García MT; Tirado-Vélez JM
Front Microbiol; 2017; 8():1447. PubMed ID: 28824578
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of sitafloxacin against clinical strains of Streptococcus pneumoniae with defined amino acid substitutions in QRDRs of gyrase A and topoisomerase IV.
Touyama M; Higa F; Nakasone C; Shinzato T; Akamine M; Haranaga S; Tateyama M; Nakasone I; Yamane N; Fujita J
J Antimicrob Chemother; 2006 Dec; 58(6):1279-82. PubMed ID: 17056610
[TBL] [Abstract][Full Text] [Related]
11. Longitudinally tracking fluoroquinolone resistance and its determinants in penicillin-susceptible and -nonsusceptible Streptococcus pneumoniae isolates in Hong Kong, 2000 to 2005.
Ip M; Chau SS; Chi F; Cheuk ES; Ma H; Lai RW; Chan PK
Antimicrob Agents Chemother; 2007 Jun; 51(6):2192-4. PubMed ID: 17371818
[TBL] [Abstract][Full Text] [Related]
12. [MALDI-ToF mass-spectrometry in analysis of genetically determined resistance of Streptococcus pneumoniae to fluoroquinolones].
Malakhova MV; Vereshchagin VA; Il'ina EN; Govorun VM; Filimonova OIu; Grudinina SA; Sidorenko SV
Antibiot Khimioter; 2007; 52(1-2):10-7. PubMed ID: 18461803
[TBL] [Abstract][Full Text] [Related]
13. Susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada.
Patel SN; McGeer A; Melano R; Tyrrell GJ; Green K; Pillai DR; Low DE;
Antimicrob Agents Chemother; 2011 Aug; 55(8):3703-8. PubMed ID: 21628545
[TBL] [Abstract][Full Text] [Related]
14. In vitro selection of resistance in Streptococcus pneumoniae at in vivo fluoroquinolone concentrations.
De Vecchi E; Nicola L; Ossola F; Drago L
J Antimicrob Chemother; 2009 Apr; 63(4):721-7. PubMed ID: 19218275
[TBL] [Abstract][Full Text] [Related]
15. Activities of fluoroquinolones against Streptococcus pneumoniae type II topoisomerases purified as recombinant proteins.
Morrissey I; George J
Antimicrob Agents Chemother; 1999 Nov; 43(11):2579-85. PubMed ID: 10543732
[TBL] [Abstract][Full Text] [Related]
16. Are fluoroquinolone-susceptible isolates of Streptococcus pneumoniae really susceptible? A comparison of resistance mechanisms in Canadian isolates from 1997 and 2003.
Schurek KN; Adam HJ; Siemens CG; Hoban CJ; Hoban DJ; Zhanel GG
J Antimicrob Chemother; 2005 Oct; 56(4):769-72. PubMed ID: 16126779
[TBL] [Abstract][Full Text] [Related]
17. Contribution of topoisomerase IV and DNA gyrase mutations in Streptococcus pneumoniae to resistance to novel fluoroquinolones.
Pestova E; Beyer R; Cianciotto NP; Noskin GA; Peterson LR
Antimicrob Agents Chemother; 1999 Aug; 43(8):2000-4. PubMed ID: 10428926
[TBL] [Abstract][Full Text] [Related]
18. Molecular epidemiology of fluoroquinolone resistance in invasive clinical isolates of Streptococcus pneumoniae in Seville.
Iraurgui P; Torres MJ; Aznar J
Enferm Infecc Microbiol Clin; 2012 Apr; 30(4):180-3. PubMed ID: 22365183
[TBL] [Abstract][Full Text] [Related]
19. Failure of levofloxacin treatment in community-acquired pneumococcal pneumonia.
Endimiani A; Brigante G; Bettaccini AA; Luzzaro F; Grossi P; Toniolo AQ
BMC Infect Dis; 2005 Nov; 5():106. PubMed ID: 16307682
[TBL] [Abstract][Full Text] [Related]
20. Emergence of fluoroquinolone-resistant Propionibacterium acnes caused by amino acid substitutions of DNA gyrase but not DNA topoisomerase IV.
Nakase K; Sakuma Y; Nakaminami H; Noguchi N
Anaerobe; 2016 Dec; 42():166-171. PubMed ID: 27793740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
